The aim of the present study is to verify whether recombinant interleukin-2 (rIL-2) at low doses is well tolerated in aggressive lymphoma in complete remission (CR), and if there may be a biological justification for its use as a remission-maintenance therapy able to reduce the percentage of relapses. We treated 6 patients with B-cell non-Hodgkin's lymphoma (B-NHL) in CR following PM-Cytabom with rIL-2 3 IMU s.c. x 5 d per wk, every other wk for 8 wk. Our results show that this treatment provokes statistically significant changes in the absolute number of lymphocytes, eosinophils, CD25(+) and CD122(+) cells and soluble IL-2 receptors; these doses, however, are not sufficient to modify CD3(+), CD16(+) and CD56(+) cell values or natural killer and lymphokine activated killer cell activity. Thus these findings do not appear to constitute a biological rationale for the use of rIL-2 at this dose and schedule as a remission-maintenance therapy in B-cell NHL. Nevertheless, the results are a valid basis for further study of the use of the same rIL-2 doses for a longer period of time in combination with other cytokines, in the hope that the biological effects can be augmented without increasing the toxic side effects.

In vivo biological response following low-dose interleukin-2 in complete remission B-cell non-Hodgkin's lymphoma patients. Italian Lymphoma Study Group (GISL) / A., Vecchi; L., Cavanna; P., Avanzini; V., Callea; V., Velardi; N., Albi; P., Tartoni; L., Bensi; P., Valentini; R., Longo; Sacchi, Stefano. - In: EUROPEAN JOURNAL OF HAEMATOLOGY. - ISSN 0902-4441. - STAMPA. - 57 (1):(1996), pp. 33-37.

In vivo biological response following low-dose interleukin-2 in complete remission B-cell non-Hodgkin's lymphoma patients. Italian Lymphoma Study Group (GISL).

SACCHI, Stefano
1996

Abstract

The aim of the present study is to verify whether recombinant interleukin-2 (rIL-2) at low doses is well tolerated in aggressive lymphoma in complete remission (CR), and if there may be a biological justification for its use as a remission-maintenance therapy able to reduce the percentage of relapses. We treated 6 patients with B-cell non-Hodgkin's lymphoma (B-NHL) in CR following PM-Cytabom with rIL-2 3 IMU s.c. x 5 d per wk, every other wk for 8 wk. Our results show that this treatment provokes statistically significant changes in the absolute number of lymphocytes, eosinophils, CD25(+) and CD122(+) cells and soluble IL-2 receptors; these doses, however, are not sufficient to modify CD3(+), CD16(+) and CD56(+) cell values or natural killer and lymphokine activated killer cell activity. Thus these findings do not appear to constitute a biological rationale for the use of rIL-2 at this dose and schedule as a remission-maintenance therapy in B-cell NHL. Nevertheless, the results are a valid basis for further study of the use of the same rIL-2 doses for a longer period of time in combination with other cytokines, in the hope that the biological effects can be augmented without increasing the toxic side effects.
1996
57 (1)
33
37
In vivo biological response following low-dose interleukin-2 in complete remission B-cell non-Hodgkin's lymphoma patients. Italian Lymphoma Study Group (GISL) / A., Vecchi; L., Cavanna; P., Avanzini; V., Callea; V., Velardi; N., Albi; P., Tartoni; L., Bensi; P., Valentini; R., Longo; Sacchi, Stefano. - In: EUROPEAN JOURNAL OF HAEMATOLOGY. - ISSN 0902-4441. - STAMPA. - 57 (1):(1996), pp. 33-37.
A., Vecchi; L., Cavanna; P., Avanzini; V., Callea; V., Velardi; N., Albi; P., Tartoni; L., Bensi; P., Valentini; R., Longo; Sacchi, Stefano
File in questo prodotto:
Non ci sono file associati a questo prodotto.
Pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11380/310551
Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus 2
  • ???jsp.display-item.citation.isi??? 2
social impact